Effect of 7-con-O-methylnogarol on DNA synthesis, survival, and cell cycle progression of Chinese hamster ovary cells.
The effect of 7-con-O-methylnogarol (7-OMEN) on the survival of exponentially growing and plateau-phase Chinese hamster ovary cells was determined in a cloning assay. After 2 hr of exposure, the 50% lethal dose for exponential and plateau-phase cells was 0.3 and 1.5 microgram/ml, respectively. Drug doses for cell progression studies were based upon drug lethality; therefore, higher doses were used for plateau than for exponential populations. The effect of 7-OMEN on cell progression was studied by DNA flow cytometry under the following conditions: (a) during 24 hr of continuous exposure of exponentially growing cells; (b) during recovery of exponential cells after 2 or 7 hr of drug exposure; and (c) during recovery of plateau-phase cells after 2 hr of exposure. Exponential cells exposed continuously for 24 hr progressed normally from M to G1 phase and from G1 to S phase, progression through S phase was slowed, and cells were ultimately blocked in G2 + M. Inhibition of S-phase progression was dose dependent, 0.2 microgram/ml having only slight effect and 1.0 microgram/ml accumulating a large fraction in S phase. Inhibition of S-phase progression correlated with DNA synthesis inhibition. Similar inhibitory effects were observed after pulsed (2- or 7-hr) exposure of exponential cells. 7-OMEN also blocked plateau-phase cells in G2 + M after 2 hr of exposure, but higher doses (3.0 microgram/ml) were required. Simultaneous exposure of exponential cells to Colcemid (which blocks cells in metaphase) and 1.0 microgram 7-OMEN per ml completely inhibited the expected increase in mitotic index, indicating that the G2 + M block observed by DNA flow cytometry was a block in G2 or prophase.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects*; D002478:Cells, Cultured; D006224:Cricetinae; D003412:Cricetulus; D004261:DNA Replication / Q000187:drug effects*; D003630:Daunorubicin / Q000031:analogs & derivatives*; D005260:Female; D017290:Menogaril; D009621:Nogalamycin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D010053:Ovary; D013997:Time Factors
D000970:Antineoplastic Agents; D017290:Menogaril; D009621:Nogalamycin; D003630:Daunorubicin